Kaye Scholer client Pfizer Inc. has entered into an exclusive worldwide licensing agreement with Gliknik Inc., a privately held biopharmaceutical company, for GL-2045, Gliknik’s recombinant stradomer™, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin.
Under the terms of the agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to the licensing agreement.
The Kaye Scholer team that advised Pfizer included Partners Adam Golden and Andres Liivak and Associates Konstantinos Yiannopoulos, Viktoriya Karshenboyem and Tracy Romano.
Also of Interest
- Tax Alert: Final Debt Regulations Have Limited Scope of Application November 30, 2016 • Client Alerts
- Best Lawyers Profiles Frankle as “Lawyer of the Year” November 28, 2016 • Media Mentions
- Fallon Appointed to the University at Albany Presidential Search Committee November 22, 2016 • Recognitions
- Fintech Term Sheet Negotiations: Key Issues Beyond Price November 21, 2016 • Articles
- JUVE Handbuch Recommends Frankfurt Office and Lawyers November 14, 2016 • Recognitions
- Using Technology Service Providers Is No Silver Bullet November 7, 2016 • Articles
- Kaye Scholer Advises Bregal, Motion Equity in Morrison Utility Services Sale November 7, 2016 • Client Successes
- Pitfalls of Present-Day Contracts: Hyperlinked Contract Terms November 7, 2016 • Articles
- Kaye Scholer Advises Biohaven on Oversubscribed Private Financing November 4, 2016 • Client Successes